Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

Impact · against what's priced in

Madrigal expands its MASH pipeline and long-term commercial strategy by acquiring ervogastat from Pfizer to develop as a combination therapy with Rezdiffra. While the acquisition strengthens Madrigal's clinical portfolio, the financial impact for Pfizer is minimal, consisting of a $50 million upfront payment for a non-core asset.

MDGL+0.70: No priced-in read yet

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

What matters in this story

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

What matters in this story

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

How each ticker is affected

Connected tickers

Track these names every morning.

Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher

Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding Franchise

$50,000 in These 5 Dividend Stocks Could Pay You $2,700 a Year

Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

What matters in this story

Next reads from the same story arc

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

What matters in this story

Next reads from the same story arc

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

How each ticker is affected

Connected tickers

Track these names every morning.

Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher

Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding Franchise

$50,000 in These 5 Dividend Stocks Could Pay You $2,700 a Year

Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?